AAPL vs JNJ: Which Is the Better Buy?
Side-by-side comparison of Apple Inc. and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-15.
Apple Inc. · Technology
$308.63
+5.6% upside to fair value
Grade B
High Quality
VS
Johnson & Johnson · Healthcare
$253.85
-21.7% upside to fair value
Grade D
High Quality
QuantHub Verdict
AAPL has more upside to fair value
(+5.6%).
JNJ trades at a lower forward P/E
(29.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
AAPL |
JNJ |
| Current Price |
$308.63 |
$253.85 |
| Fair Value Estimate |
$325.93 |
$198.76 |
| Upside to Fair Value |
+5.6%
|
-21.7%
|
| Market Cap |
$4,533.0B |
$611.1B |
| Forward P/E |
37.2x
|
29.3x
|
| EV / EBITDA |
28.6x
|
19.2x
|
| Price / Sales |
10.0x
|
6.3x
|
| Price / FCF |
35.1x
|
34.3x
|
| Revenue Growth YoY |
+16.6%
|
+9.9%
|
| Gross Margin |
47.9%
|
69.1%
|
| Operating Margin |
32.6%
|
26.9%
|
| Return on Equity |
146.7%
|
26.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.85%
|
2.91%
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
Apple Inc. is a leading technology company specializing in consumer electronics, software, and services, with a durable competitive moat driven by its integrated ecosystem of devices, operating systems, and services. The company benefits from strong brand loyalty, high margins with a gross margin of 47.9%, and consistent earnings growth, including a 19.4% increase in earnings in the most recent q…
Johnson & Johnson is a leading healthcare conglomerate operating primarily in the drug manufacturing sector, known for its durable competitive moat supported by strong brand recognition and intangible assets. The company exhibits high business quality with a 26.3% return on equity and robust gross and net margins of 69.1% and 21.8%, respectively. However, earnings have faced significant pressure,…
Accumulation Zones
| Metric |
AAPL |
JNJ |
| Zone Low |
$244.45 |
$149.07 |
| Zone High |
$277.04 |
$168.95 |
| In Buy Zone? |
No
|
No
|